GSK Pharma reported a healthy set of earnings for the quarter ended June, with consolidated net profit rising 15.7% year-on-year as revenue and operating profit registered double-digit growth.
The pharmaceutical company posted a consolidated net profit of Rs 237 crore for the first quarter, compared with Rs 205 crore in the year-ago period, according to the company's earnings statement.
-
Indian Markets Turning Corner After Two Tough Years, Says Sandeep Tandon -
NDTV Profit Ignite 2026: Experts See Opportunity In Equities, Stay Bullish For Long-Term -
Buy Right, Sit Tight Does Not Work for Individual Stocks, Says Dinshaw Irani -
'Worst Is Behind': Quant MF Sees Market Bottom, Flags 'Extreme Euphoria' In Midcaps -
India's Mutual Fund Industry Could Become A $1 Trillion Opportunity, Say Fund Managers -
'Foreign Investors Are Baraatis': Raamdeo Agrawal's Take On LTCG Tax -
Stay Invested Through Market Cycles: Raamdeo Agrawal at NDTV Profit Ignite -
Ramesh Damani Remains Bullish On India For Next 20-30 Years, Sees Bargains Amid Market Weakness -
CAS Came After A Long Consultation Process: SEBI Chairman Tuhin Kanta Pandey AT NDTV PROFIT IGNITE -
Aim To Cut FPI Onboarding Time From Mth To Five Days: SEBI Chairman Tuhin Kanta Pandey AT NDTV PROFI
ALSO READ: Jindal Stainless Q1 Results: Profit Slides 8% As Margin Narrows; Revenue Flat
Also Read | Layoffs Are Rising In Tech, But These Skills Are Helping People Unlock Better Pay
Revenue from operations increased 16.5% to Rs 938 crore from Rs 805 crore a year earlier.
Operating performance also strengthened during the quarter. EBITDA rose 17.6% year-on-year to Rs 295 crore, while the EBITDA margin improved to 31.5% from 31.2% in the corresponding quarter last year, the company said.
Separately, the company's board has re-appointed Bhushan Akshikar as Managing Director for a further term of two years, according to the filing.
ALSO READ: Ather Energy Q1 Results: Net Loss Narrows As Revenue Soars 89%
GSK Pharma Q1 Result Highlights (Cons, YoY)
- Net Profit rises 15.7% at Rs 237 crore versus Rs 205 crore.
- Revenue rises 16.5% at Rs 938 crore versus Rs 805 crore.
- Ebitda rises 17.6% at Rs 295 crore versus Rs 251 crore.
- Margin at 31.5% versus 31.2%.
- Re-appoints Bhushan Akshikar as MD for 2 years.
Essential Business Intelligence, Sharp Market Insights, Practical Personal Finance Advice, Daily Fuel, Gold and Silver Prices and Latest Stories — On NDTV Profit.
